Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (238)	1/27/2005 5:04:20 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 447

OSIP I posted this comment and question on Yahoo. I will post the answer if I get one: Hi Ricardo, CNBC ran an segment on a doctor with colorectal cancer who was being treated with Erbitux. They also mentioned that a study supported by Sloan Koettering in 16 patients who did not express EFGR had 4 patients who had greater than 50% shrinkage in tumors and 2 who had less than 50% shrinkage. (Study published in the Journal of Clinical Oncology) A Dr. L Saltz commented that these findings "blow out of the water the current thinking" that Erbitux should be used for patients expressing EGFR. This makes me* wonder if we will see a similar advantage to Tarceva that goes beyond the EGFR patients. Is this reasonable or am I wacky? ij